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Abstract 
The UK introduced the 7-valent pneumococcal conjugate vaccine (PCV7) into the national 
childhood immunisation programme in 2006, which was replaced with the 13-valent PCV 
(PCV13) in 2010. The published articles presented in this thesis assessed the impact of PCVs 
on invasive pneumococcal disease (IPD) especially in children and those with underlying 
comorbidities, particularly sickle cell disease (SCD). 
The systematic review of PCV failures found a low incidence of vaccine failures irrespective 
of the PCV used in the national immunisation programme. After PCV7 introduction, 
serotypes 19F and 6B were responsible for more than two-thirds of vaccine failure cases. In 
keeping with published studies, these serotypes were also responsible for most cases of 
vaccine failure in the national surveillance of PCV failures in England and wales before the 
introduction of PCV13. After PCV7 was replaced with PCV13, serotypes 3 and 19A were 
over-represented among the vaccine failure cases. Overall case fatality rate  (CFR) in children 
with PCV failure was low, with only six of 161 children (4%) dying, including five (83%) 
who had significant underlying comorbidities. 
A review of IPD in children with SCD however identified continued increased risk of IPD in 
children with SCD. The overall CFR among published cases was 11.5%. More than half of 
the serotypes associated with IPD were not included in the PCV13, of which more than half 
were due to serogroup 15. Similarly, in the enhanced national surveillance of IPD in children 
with SCD, in England, it was identified that there were 881 IPD cases, including eleven 
children homozygote for haemoglobin S (HbSS) and one double heterozygote for 
haemoglobin S and C (HbSC). Children with SCD remained 49 times more likely to develop 
IPD and 5 times more likely to die of their infection compared to their healthy peers. Most 
IPD cases in SCD were also due to serotypes that were not covered by PCV13, particularly 
serogroup 15, and this finding was found to be consistent with published literatures. 
Research was also carried out to determine the epidemiology of pneumococcal meningitis 
following the introduction of PCV in England and Wales. The incidence of pneumococcal 
meningitis did not change after PCV7 introduction, but declined by 48% after the vaccine 
was replaced with PCV13 in keeping with large reductions in cases due to the additional 
PCV13 serotypes 7F and 19A. Currently, meningitis due to PCV13 serotypes is rare and the 
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non-PCV13 serotypes 8 and 12F are the predominant causes of pneumococcal meningitis. 
Additionally, while the incidence of pneumococcal meningitis has declined, the CFR has 
remained high at 17.5%. However, childhood CFR for IPD remained low at 4.8%, with more 
than half (59%) of deaths occurring in infants, mainly in those aged <3 months who 
accounted for 28% of all fatal cases. Overall, 35% of children who died had underlying risk 
factors for IPD while meningitis was responsible for 47% of IPD-related deaths.  
 
In summary, this thesis has demonstrated that the rate of PCV failure, irrespective of the 
vaccine used or schedule, was very low, as was CFR in children with PCV failure. Most 
children with PCV13 failure were healthy, developed LRTI, and survived their infection 
without long-term complications. The continuing low prevalence of PCV7 failures after 
PCV13 introduction is reassuring and it is likely that PCV13 failure will also decline in the 
coming years. However, children with SCD remained at risk of IPD and death despite these 
measures of daily penicillin prophylaxis as well as pneumococcal vaccination. The majority 
of serotypes causing IPD in SCD are no longer vaccine preventable, therefore every effort 
should be made to ensure that these children adhere to penicillin prophylaxis and 
pneumococcal vaccines.  
Thus, in conclusion, PCVs are highly effective in preventing IPD due to the respective 
vaccine serotypes. The childhood pneumococcal vaccination programme has led to a 
significant reduction in the incidence of IPD, including meningitis. However, compared to 
other clinical presentations, there was a lower than expected impact on pneumococcal 
meningitis, with case fatality rates due to meningitis remaining relatively unchanged across 
the age groups. Given that most IPD cases, including meningitis are now due to non-PCV13 
serotypes, including most fatal IPD cases, additional strategies need to be introduced to 
reduce childhood pneumococcal deaths in countries with established pneumococcal 
vaccination programmes.  
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                                   CHAPTER 1 
 
Introduction 
 
1.1 Invasive and Non-invasive Pneumococcal Disease 
Streptococcus pneumoniae (pneumococcus; S. pneumoniae) is a leading cause of morbidity 
and mortality in children and adults worldwide (WHO., 2007). It colonises the nasopharynx 
but can cause mild localised infections such as sinusitis and otitis media; rarely, the 
pneumococcus is responsible for occasionally more severe, invasive pneumococcal disease 
(IPD). The most common clinical presentations of IPD include bacteremic pneumonia, 
septicaemia, and meningitis. Diseases caused by pneumococcus are a major public health 
problem, both in terms of the large burden of non-invasive diseases such as otitis media, 
sinusitis and pneumonia, as well as the poor outcomes associated with more severe invasive 
infections including septicaemia and meningitis (Russel et al., 2011; Drijkoningen et al., 
2014; ACIP., 2000; Butler et al., 1999). The magnitude of the burden caused by non-invasive 
cases both in the developed and developing countries is hard to define because the cause is 
not usually determined, including pneumococcal disease among elderly people in developing 
countries (WHO., 2007). In addition to the high case fatality rates, those surviving 
pneumococcal diseases, especially the most severe manifestation such as pneumococcal 
meningitis, often have significant long-term complications. In a meta-analysis including 48 
studies from industrialised countries, 32% of individuals with pneumococcal meningitis had 
sequelae, including hearing loss, seizures, acquired brain injury and visual impairment (Jit., 
2010). Also, in a recent prospective multicentre study involving 155 children in China, 30.3% 
had neurological complications on long-term follow up (Wang et al., 2019).  
 
1.1.1 The Pneumococcus and Pneumococcal Serotypes 
S. pneumoniae is a Gram-positive, encapsulated diplococcus and resides asymptomatically in 
the nasopharynx of healthy carriers without causing any symptoms. The organism is 
transmitted by direct contact with respiratory secretions from patients and healthy carriers. 
 
 
 
 
 
 
15 
Transient nasopharyngeal colonisation, not disease, is the normal outcome of exposure to 
pneumococci. The highest carriage rates are in young children, with reported rates of 30% to 
50% (van Hoek et al., 2014). Factors associated with higher carriage rates include age <2 
years, nursery attendance and out-of-home childcare, crowding, winter and parental smoking 
(Lexau et al., 2005). Occasionally, S.pneumoniae may invade locally to cause non-invasive 
mucosal infections such as sinusitis, otitis media and pneumonia.  In susceptible individuals, 
particularly the immunocompromised, older adults and young children, S. pneumoniae 
infection can lead to invasive disease, including septicaemia, bacteraemic pneumonia, and 
meningitis, as well as other less common secondary localised infections such as septic 
arthritis, osteomyelitis, endocarditis and periorbital cellulitis (ACIP., 2000). 
The polysaccharide capsule of S. pneumoniae is an essential virulence factor for invasive 
disease. Their unique polysaccharide capsule is used to distinguish between the different 
pneumococcal strains serologically. More than 97 different pneumococcal serotypes have 
been identified and most serotypes can cause invasive and non-invasive disease (Geno et al., 
2015). These serotypes are distinguished using either the American or Danish systems. The 
Danish system was able to distinguish serogroups from serotypes. Most American serotypes 
corresponded to the Danish serotypes, except for Danish serotype 35A, which corresponded 
to American types 47 and 62 (Kauffmann et al., 1960). This Danish system has now been 
widely accepted throughout the world.   
Recent acquisition of the pneumococcus is associated with IPD, although, not all 
pneumococcal serotypes are equally invasive; the composition and quantity of capsular 
polysaccharide has a major role in virulence and invasive potential. Most pneumococcal 
capsules are anionic and therefore negatively charged, except the capsules of serotypes 7A, 
7F, 14, 33A, 33F, and 37, which are not charged (Lin et al., 2013). Serotype 1 capsule 
contains both a positive and a negative charge (Bentley et al., 2006), and therefore has a 
relatively high rate of invasion compared to its rate of colonisation (Brady et al., 2014). The 
less soluble nature of serotype 14 capsule compared to other serotypes makes it have a more 
impermeable barrier and this may explain its relatively invasive nature (Brady et al., 2014). 
In addition, genetic variations of this polysaccharide capsule also play a role. Currently four 
genes have been identified, namely wze, wze, wzg and wzh (otherwise known as cpsA, cpsB, 
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cpsC and cpsD, respectively). A detailed biochemical structure of pneumococcal capsules is 
beyond the scope of this thesis. However, studies suggest that the genetic make-up of the 
polysaccharide capsule has less of an impact on invasiveness than the capsular type 
(Hausdorff et al., 2000). 
Apart from the pneumococcal capsule, other combinations of virulence factors have been 
implicated in the ability of pneumococcus to evade the host immune response and spread 
from the nasopharygnx to the sterile part of the body, causing pneumonia and other IPD. For 
example, the pneumococcal cell wall consists of peptidoglycan, the teichoic and lipoteichoic 
acids. These glycan chains can undergo secondary modifications, making the cell resistant to 
(Gisch N et al., 2015; Bui et al., 2012). The phosphorylcholine produced by the cell wall are 
also important for evasion of host immune responses, as well as the pili, enabling 
the attachment and colonization by the pneumococcus in order to evade phagocytosis (van 
der Poll et al., 2009). 
S. pneumonia also produces an autolysin which degrades the cell wall releasing toxins such 
as pneumolysin which promote colonization (Jedrzejas., 2001), enhance the formation of 
biofilms, and reduces mucus clearance and phagocytosis (Steel HC, Cockeran R, Anderson R 
2013)(Steel et al, 2013). It can also interfere with the host’s immune system and has been 
implicated in the regulation of the complement system (Mitchell et al., 2010). In addition, the 
pneumococcus produces pneumococcal surface proteins which acts as adhesins to host cells 
and inhibit the host’s immune system (van der Poll et al., 2009; Jedrzejas., 2001). 
Immunoglobin (Ig) A1 proteases which reduces the binding IgA’s effector region of the 
heavy chain and obstruct the destruction of pneumococcus by these antibodies (Janoff EN et 
al., 2014; Chi YC et al., 2017).  
Thus, while certain serotypes are infrequently isolated from the nasopharynx, they contribute 
disproportionately to IPD. In large studies, serotypes 1, 2, 4, 5, 7F, 8, 9,12F, 14, 16, 18C, and 
19A were found to be more invasive compared to serotypes 3, 6A, 6B, 11A, 15B/C, 19, and 
23F, which were generally less invasive (Kronenberg et al., 2006; Sleeman et al., 2006; 
Brueggemann et al., 2003; Sá-Leão et al., 2011; Rivera-Olivero et al., 2011; Yildirim et al., 
2010). The primary function of the capsule in virulence is to shield the cell wall from reacting 
with host antibodies and complement (Kim et al.,1999). This function is likely to vary 
depending on the host immunity and their capacity to elicit the host antibody response. 
Serotypes that are poorly immunogenic in young children are often associated with virulence 
among children (Robbins et al.,1983). Similarly, certain serotypes are known to be less 
pathogenic in human. For example with serotype 27 and 11, the C-reactive protein and 
ficolin-2 directly binds with the capsule respectively, making them largely non-pathogenic 
(Brady et al., 2014; Edwards et al.,1982), suggesting that patients infected with a low 
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virulence serotype are likely to lack the ability to amount a protective mechanism against that 
serotype or have a defect in their immune system. 
Population-based studies have also identified significant associations between specific 
pneumococcal serotypes and disease severity (e.g. death) among patients with septicaemia 
(Harboe et al., 2009) and pneumonia (Weinberger et al., 2010), but not meningitis. In a meta-
analysis that evaluated serotype-specific pneumococci, it was found that serotypes 1, 7F, and 
8 were associated with a lower odds of death, whereas serotypes 3, 6A, 6B, 9N, and 19F were 
associated with a higher risk of death (Weinberger et al., 2010). 
Although there are significant geographical variations, with different serotypes dominating in 
different regions, common serotypes are consistently identified throughout the world. These 
variations are thought to be due to the results of age, time and possible environmental 
influences (Hausdorff et al., 2000).  In children, prior to the routine PCV immunisation 
programme, the seven most common serotypes were responsible for 60-80% of all IPD in 
children (Robbins et al., 1983).  
 
1.1.2 The Burden of Pneumococcal Disease 
Pneumococcal disease remains a leading cause of vaccine-preventable child death and illness 
despite there being continuing reductions in both overall childhood mortality and pneumonia 
deaths. Unlike IPD where there are established surveillance systems, the overall burden of 
non-invasive pneumococcal disease is difficult to measure. It is estimated globally that there 
were 120 million episodes of non-bacteraemic pneumonia in 2010 in developing country, 
resulting in 1.3 million deaths in children younger than 5 years (Walker et al., 2013). Before 
the introduction of PCVs in low income countries, of the estimated 8.8 million global annual 
deaths amongst children <5 years of age in 2008, 476 000 deaths were caused by 
pneumococcal infections in HIV-negative children (WHO., 2008). Children and adults with 
underlying comorbidities have a much higher risk of serious pneumococcal disease and death 
(O’Brien et al., 2009). The highest burden of pneumonia deaths is in Africa and Southeast 
Asia, which together account for almost one million of the estimated 1.3 million pneumonia 
deaths worldwide in children under 5 years of age in 2011 (Walker et al., 2013), and a 
significant proportion of those deaths could arguably have been prevented through 
vaccination. However, in industrialised countries, where fatality from IPD is rare, little is 
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known of the characteristics children who died of IPD in the era of conjugate vaccines.   
The incidence of IPD in children aged <5 years is also much higher in developing countries 
than industrialised countries for a number of reasons, including malnutrition, poverty, and 
overcrowding. Data from developing countries are generally underestimated due to 
inadequate facilities to establish diagnosis, self-medication and poor surveillance systems. 
For example, in South Africa, prior to PCV introduction, the incidence of IPD in < 2years 
among HIV uninfected children was 28.6/100,000, while in Gambia the incidence was 
estimated to be 253/100,000 in a similar age-group (Mackenzie et al., 2016). In developed 
countries too, the reported incidence in children <5 years old in the pre-PCV era has been 
variable, ranging from 17.1 to 94.7 cases/100,000 child-years, with the highest incidence in 
North-America and lowest in European countries (Izurieta et al., 2018).  
 
In adults, the annual incidence of IPD ranges from 15 to 49 per 100 000 in North America, 
whereas from Europe, during the same period, the rates ranged from 11 to 27 per 100 000 
(Kyaw et al., 2003; Reinert et al., 2005; Lynch et al., 2009). S.pneumoniae is the most 
common cause of community-acquired bacterial pneumonia (CAP) in adults. The incidence 
of CAP rises rapidly with increasing age, with estimated rates ranging from 18.2 per 1000 
person-years in people aged 65–69 years, to 52.3 per 1000 person-years in those aged over 85 
years (Jackson et al., 2004). Case fatality from CAP also increases with age, being 2.2% 
versus 10.3% in these two age-groups respectively, determined from studies using a large 
Spanish cohort (Vila-Corcoles et al., 2005). Amongst those with underlying co-morbidity, 
those with predisposing factors for IPD and elderly patients with severe CAP requiring 
mechanical ventilation case fatality rates of more than 50% have been reported (El-Solh et 
al., 2001). Robust data on the burden of pneumococcal disease in adults and elderly people in 
developing countries, especially relating to pneumonia, are lacking (Maimaiti et al., 2013). 
Generally, adults with underlying co-morbidities and older adults are more vulnerable to 
serious bacterial infection and are also less likely to develop robust immune responses to 
vaccination (Weycker et al., 2010). The ageing human population, especially in developed 
countries, poses a major challenge and will lead to a rise in the healthcare and economic 
burden for pneumococcal diseases worldwide. In the US, in 2004, it was estimated that the 
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direct healthcare costs of pneumococcal disease totalled $3.5 billion (Huang et al., 2011). A 
similar study in Europe estimated that the total healthcare costs for CAP could be as high as 
$11.7 billion annually, with one third related to indirect costs, such as loss of working days 
(Gibson et al., 2003). It was therefore clear, that a long lasting solution was needed to curb 
the burden of pneumococcal disease in developing and industrialised countries. In 2000, 
PCV7 was introduced in the US and later adopted in the national immunisation programme 
by many other countries. 
 
 
 
1.1.3 The History of Pneumococcus 
 
The pneumococcus was first isolated by the US Army physician George Sternberg and the 
French chemist Louis Pasteur in 1886 independently, following its role as a major cause of 
pneumonia (Sternberg., 1881; Pasteur., 1881). In 1920, due to its characteristic appearance on 
Gram stain, it was renamed Diplococcus pneumoniae (Winslow et al., 1920), which was 
Mean annual incidence of invasive pneumococcal disease, by age and sex, in England and 
Wales, 1995–1997, and in the Oxford region, 1995–1999. 
Karen et al. J Infect Dis. 2001 
Age Distribution of Pneumococcal Diseases 
Inability to mount immune 
response  to capsule 
 
 
 
 
 
 
20 
changed to Streptococci pneumoniae in 1974, since it had similar features to other bacteria in 
the streptococcus group.  S. pneumoniae has played a critical role in human disease. Its 
capsular polysaccharide is known to be pivotal to its virulence.  
However, it was not until the work of Griffith, that bacteriologist believed that hereditary 
information could only be transferred by descent, from one generation to another rather than 
horizontally, from one cell to another. Griffith worked with 2 strains of pneumococcus, rough 
(R) and smooth (S). The rough (R) strain was non-pathogenic and lacks capsule while the 
smooth (S) strain was pathogenic and has a capsule covering the cell wall. The injected R 
strain and killed (heated) S strain on separate mice did not cause a disease, while the injected 
S strain result in the death of the mice. However, when both the killed S strain and the R 
strain where injected together, the mice died, and only the live S strain was obtained from this 
dead mice, suggesting that the type R strain had been transformed into the virulent S Strain 
by the a ‘transforming principle’.  Studies of the rough and smooth colony variants of a 
pneumococcal strain showed that serotype-specific protective sera react with the capsule 
(Griffith., 1928).  The chemical nature of the capsule was then elucidated to be 
polysaccharide (Heidelberger and Avery., 1924). Griffith experiment was therefore the first 
to suggest that pneumococcus are capable of transferring genetic information by 
transformation. This was verified by Avery and colleague, which is now known as DNA 
(Avery and Dubos., 1931). 
These findings and work by other scientists opened the door for a number of studies in the 
1930s and 1940s on vaccines aimed at preventing pneumococcal disease. In 1937, for 
example, Felton’s capsular material was successfully used in a program of mass vaccination 
to abort an outbreak of pneumonia at a state hospital (Smillie., 1938).  
In addition, the discovery of the antibacterial properties of the fungus-derived substance that 
came to be called penicillin by Fleming in 1929 completely changed the approach to 
treatment of pneumococcal infections (Fleming., 1929). This led to great successes in the 
treatment of a variety of staphylococcal and streptococcal (including pneumococcal) 
infections, especially those resistant to sulfonamides (Keefer et al., 1943).  
However, penicillin-resistant (MIC of >0.1microgram/ml) pneumococcal strains emerged in 
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the 1960s and 1970s. In the 1980s, in addition to penicillin, erythromycin and trimethoprim-
sulfamethoxazole continue to spread globally. Multidrug-resistant pneumococci strains were 
first identified in children (Jacobs et al., 1978) and were observed among isolates of serotypes 
1, 14, 19F, 19A and 23F in 21 European countries in the 21st century (European Centre for 
Disease Prevention and Control., 2012). The mechanism by which resistance to penicillin 
arises in pneumococci involves decreased binding of the drug to penicillin binding proteins 
(PBPs), which are also known as transmembrane carboxypeptidases-enzymes involved in cell 
wall synthesis (Jacobs et al., 1978). Later, Hotchkiss (Hotchkiss., 1951) showed that, in 
addition to the genes encoding capsule production, those sequences encoding resistance to 
penicillin could be transferred to a previously penicillin-sensitive pneumococcus by DNA 
isolated from a penicillin-resistant Pneumococcus. This study opened up investigations into 
biochemical principles that underpin genetic transference of information. For example whole-
genome sequencing is now been used in the population to study the epidemiology of capsule 
switching to non-vaccine serotypes following the introduction of conjugate vaccines and the 
emergence of drug resistance (Croucher et al., 2013). The increasing incidence of penicillin-
resistant pneumococci continues globally. In the US, prior to the introduction of conjugate 
vaccines, 25.1% of all IPD isolates were due to penicillin-nonsusceptible strains, with 
serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F accounting for 80% of the resistant strains 
(Hofmann et al., 1995; Kyaw et al., 2006). Similar observation was made in the UK with a 
2.5% rise in penicillin resistance between 1990 and 1995 (Goldsmith et al., 1997). In the UK, 
however, the proportion of dual resistance has remained low post PCV between 2%-4% for 
erythromycin, tetracycline and penicillin, with only 2% resistant to all three antibiotics 
(Health Protection Report., 2016). Data from 38 countries looking at antibacterial resistance 
over time using their genetic constituents and other methods showed that almost 40% of 
pneumococci display multidrug –resistant phenotypes (Farrell et al., 2008).  However, the 
introduction of conjugate vaccines has changed the epidemiology of these resistant strains 
with significant reduction in resistant strains albeit with serotype replacement. Newer 
antibiotics, as well as different preventive and therapeutic strategies, are therefore needed to 
combat this trend. 
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1.1.4 Risk Factors for Pneumococcal Disease  
Certain groups of people are at higher risk of IPD (Salisbury et al., 2006). In the USA, prior 
to the introduction of PCV7, African American, Alaska Natives, and some American Indian 
populations had increased risk of IPD compared to Caucasian populations. The extent to 
which increased risks are attributable to factors other than race and ethnicity are not clear. 
The increased risks of race persist despite controlling for income (Singleton et al., 2007). In 
one study, IPD was more common in blacks than in whites (CDC., 2013).  
In addition, a number of case control studies have also demonstrated a strong association of 
IPDs with the presence of underlying disease, environmental factors, larger family size, and 
with attendance at out-of-home childcare in the preceding 3 months, suggesting that factors 
other than ethnicity also contribute to a higher infection risk (Nuorti et al., 2010). Children 
with sickle cell disease (SCD) or with human immunodeficiency virus (HIV) infections, 
especially 2 year-olds, have a markedly higher incidence of IPD, as do those with asplenia, 
nephrotic syndrome, immunodeficiency, immunosuppressive therapy and conditions 
associated with cerebrospinal fluid leak. Children with a cochlear implant, in particular those 
who received an implant with positioner, also have been shown to be at increased risk of 
pneumococcal meningitis (van Hoek et al., 2012).  
In a study assessing the risk of IPD in HIV infected children, a 9- to 43-fold increased 
relative risk of IPD was observed (Bliss et al., 2008). Even with the routine use of highly 
active retroviral therapy (HAART), the incidence of IPD was only reduced by 50% in HIV-
infected children compared to age matched, HIV uninfected children (Nunes et al., 2011).  
 
1.1.5 Pneumococcus-influenza virus co-infections 
 
Evidence suggests that many pathogens interact. A pathogen can affect the severity 
susceptibility and infectivity of another pathogen. This is particularly true for S. pneumoniae 
and viruses, which are considered as a primary risk of IPD. This role of viruses particularly 
Influenza A in facilitating the progression of S. pneumoniae infection was clearly 
demonstrated in the 20th century pandemics (Morens et al., 2008; Brundage et al., 2008; 
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Chien et al., 2009). This was corroborated in the recent trend of the 2009 H1N1 pandemic, 
where there was 17,000 fatalities reported by WHO, of which majority were due to co-
infection with S. pneumonia. Epidemiological and clinical evidence also suggests that an 
increased incidence of pneumococcal disease occurs during non-pandemic periods, 
characterised by peaks during the winter months (Dowell et al., 2003).  
 
However, the mechanism by which Influenza A increases the incidence of IPD remains 
unclear. One of the first proposed mechanisms is the destruction of the respiratory epithelium 
by Influenza A, enhancing the adherence of pneumococcus to the exposed basement 
membranes (Harford and Hara., 1950; Harford et al., 1949). Other recent mechanisms have 
been suggested to include, Influenza A induced neutrophil dysfunction, with excessive influx 
into the lungs, resulting in lung damage and increase mortality(Karlström et al., 2011), 
increased bacterial adherence due to virus-induced changes in adherence receptors and 
alterations in innate signalling and other cellular responses (McCullers., 2006). Others have 
also postulated that the production of interferon-y (IFN-y) by activated T cells which result in 
decreased in binding and phagocytosis by macrophages of S. pneumoniae (Ludewick et al., 
2011), while the role of dendritic and natural killer cells remains unclear (Olliver et al., 
2011). In contrast, in one study involving 796 nasopharyngeal aspirates from hospitalised 
patients with any respiratory viruses using real-time multiplex PCR, 50% were colonize with 
S. pneumoniae, and codetection was associated with reduced severity of viral LRTI (Jung et 
al.,  2020). However, despite reasonable amount of work on the effect of Influenza A on S. 
pneumoniae, there is a paucity of research regarding the effect of the pneumococcus on viral 
infection. 
 
1.2 Pneumococcal Vaccines 
1.2.1 Pneumococcal Conjugate Vaccines 
There are currently two types of pneumococcal vaccines licensed, the plain polysaccharide 
vaccine and the polysaccharide-conjugate vaccine. The first plain polysaccharide 
pneumococcal vaccine contained purified capsular polysaccharide antigen from 14 different 
pneumococcal serotypes. In 1983, a 23-valent polysaccharide (PPV23) was licensed in the 
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US, and included 11 additional serotypes to PCV13, including 2, 8, 9N, 10A, 11A, 12F, 15B, 
17F, 20, 22F, and 33F. The plain polysaccharide vaccines were poorly immunogenic; the 
polysaccharide antigens were not processed by antigen-presenting cells (APC) but interacted 
directly with B cells to induce antibodies in the absence of T-cells (i.e. thymic independent). 
Such T cell-independent responses were restricted in a number of ways. Most importantly, 
they failed to induce significant and sustained antibody concentrations in young children 
below the age of 18 months, who had the highest risk of IPD (Kelly et al., 2005; Baker 1992; 
Käyhty et al., 1984).  
In order to overcome this problem, protein-polysaccharide conjugate vaccines were 
developed. The conjugation of pneumococcal polysaccharide to carrier proteins elicits a T-
cell dependent immune response, which is characterised by the differentiation of memory B 
cells and much higher antibody concentrations, resulting in (i) the induction of 
immunological memory, (ii) antibody class switching and (iii) avidity maturation of the 
resulting antibodies. 
There are three different polysaccharide-conjugate vaccines, although PCV7 has now been 
replaced with PCV13:  
 The 7-valent pneumococcal conjugate vaccine (PCV7) contains polysaccharide from 
seven common capsular types (PCV7). These polysaccharides are conjugated to 
diphtheria cross-reacting material (CRM197).  
 The 10-valent PCV (PCV10) includes 3 extra serotypes: 1, 5, and 7F 
 13-valent pneumococcal conjugate vaccine (PCV13) contains three more serotypes in 
addition to PCV10: 3, 6A, and 19A. 
 
All the pneumococcal vaccines are inactivated and, since they do not contain live organisms, 
they cannot cause disease in the host. In the US, PCV7 was licensed and introduced into the 
national immunisation programme (NIP) in 2000 with a catch-up for children up to 2 years of 
age. In Australia, it was introduced in 2002 and was initially recommended for high-risk 
children, but in 2005 PCV7 was included in the NIP for all children. In Europe, PCV7 was 
licensed in 2001 and introduced into the national immunization programs (NIPs) as a 
universal childhood vaccine around 2006–2008. Its introduction into the NIPs in different 
 
 
 
 
 
 
25 
countries varied, with some countries initially only recommending vaccination for high-risk 
children before generalising administration to all children (e.g., UK, Germany, and France). 
 
1.2.2 Pneumococcal Polysaccharide Vaccines 
The 23-valent pneumococcal polysaccharide vaccine (PPV23) protects against 16 more 
serotypes compared to PCV7 and, in many countries, has been recommend for at-risk persons 
aged 2 years and above and the elderly. Studies have shown some short-term effectiveness 
against both invasive (Andrews et al., 2012) and non-invasive (Ansaldi et al., 2005; Kim et 
al., 2019) disease caused by the vaccine serotypes but its use in at-risk individuals and in the 
elderly has been controversial (Vadlamudi et al., 2019). With poor vaccine uptake compared 
to the childhood programmes and little or no overall impact observed on disease incidence, it 
has been suggested that future PCVs should include these additional PPV23 serotypes, which 
are now the main cause of IPD in countries with established immunisation programmes with 
the current higher-valent PCVs. 
 
1.2.3 Impact of Pneumococcal Vaccination on Invasive Pneumococcal Disease 
Following the introduction of PCV7 into national childhood immunisation programmes, most 
countries have reported a significant decline in IPD caused by PCV7 serotypes, not only in 
the vaccinated cohorts but also in older unvaccinated cohorts because of indirect (herd) 
protection (Davis et al., 2013). Widespread availability of PCVs also reduced the number of 
deaths due to IPD in children under 5 years of age, from over 800,000 annual deaths before 
PCV introduction to 541,000 deaths in 2008 (O’Brien et al et al., 2009; WHO., 2008). 
Significant reductions in carriage of PCV7 serotypes in vaccinated young children has 
demonstrated that nasopharyngeal carriage in infants and toddlers was an important driver of 
pneumococcal transmission in the household and wider community (Hennessy et al., 2005). 
Similar conclusions were drawn in a systematic review assessing nasopharyngeal carriage in 
children after the introduction of pneumococcal conjugate vaccination (Cohen et al., 2011). 
However, the overall carriage rate in children have remained unchanged because PCV7 
serotypes were replaced with non-PCV7 serotypes in carriage and, consequently, in disease 
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(Conklin et al., 2014). Despite the increase in serotype replacement disease due to non-PCV7 
serotypes, overall IPD rates, especially in developed countries with high vaccine uptake, have 
declined significantly in across all age groups and especially in the vaccinated cohort (Kaplan 
et al., 2013). In the UK, an overall reduction of 37% compared to the pre-PCV7 period was 
observed across all age-groups through a combination of direct and indirect (herd) protection 
(Waight et al., 2015).  
Other countries that introduced PCV7 also observed similar rapid reductions in overall and 
PCV7-serotype IPD, with variable extent of replacement disease (Gilmour et al., 2008; 
Kellner et al., 2005; Zangeneh et al., 2011; WHO et al., 2007). In the review published by 
Myint et al, on the impact of PCV7 on IPD in Europe, vaccine-type IPD reduction ranged 
from 39.9% in Spain to 99.1% in the United States with a median rate reduction of 90.1% 
(Myint et al., 2013). Other countries also observed replacement with non-vaccine serotypes, 
in both carriage and disease, following the successful implementation of PCV7 (Miller et al., 
2011; Weinberger et al., 2011; Singleton et al., 2007; Park et al., 2010). The impact of PCVs 
on pneumococcal meningitis in countries with established pneumococcal immunisation 
programmes has been variable, with some countries reporting significant reductions after 
PCV7 introduction and others reporting no change, or a decline only after PCV13 
introduction (Ben-Shimol et al., 2017; Alari et al., 2016; Hsu et al., 2009; Ruiz-Contreras et 
al., 2017; Tsai et al., 2008; Liset et al., 2015).  
The main replacing serotypes varied in different countries but some of the emerging 
serotypes were consistently common, including serotypes 6C, 19A, 22F, 15 and 33 (Jacobs 
2008; Park et al., 2008; Pelton et al., 2007). Replacement disease with serotype 19A was a 
particular problem in many parts of the world, but especially in the US, because this serotype 
was associated with resistance to multiple antibiotics (Pai et al., 2005; Yildirim et al., 2012). 
Since PCV7 licensure, two higher-valent vaccines (PCV10 and PCV13) were licensed after 
they were shown to elicit an adequate immune response against all the vaccine serotypes with 
demonstrable non-inferiority against the serotypes they have in common with PCV7 
(Vanderkooi et al., 2012).The effectiveness of these vaccines was described with a 0.92% 
vaccine failure rate per 100,000 person years over 8 years surveillance (in a 10 birth cohort) 
in England and Wales and 2% rate in a systematic review of the literature (Oligbu et al., 
2017a; Oligbu et al., 2016). 
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Globally, the introduction of higher-valent PCVs, including those countries with established 
PCV programmes, has led to additional reductions in overall IPD rates, albeit with some 
serotype replacement in carriage and disease with new emerging serotypes. Currently, the 10 
most common serotypes causing IPD in Europe include (in order of frequency) 8, 3, 22F, 
12F, 19A, 9N, 7F, 15A, 33F, 10A, accounting for 62% of typed isolates. Of the cases in 
children under 5 years of age, 72% were caused by a serotype not included in any PCV. 
Among cases aged 65 years and over, 71% were caused by a PPV23 serotype, and 32% were 
caused by a PCV13 serotype especially in the elderly (European Centre for Disease 
Prevention and Control., 2017). 
 
1.2.4 Impact of Pneumococcal Vaccines on Pneumonia 
Prior to PCV introduction, a randomised controlled trial (RCT) conducted in the Gambia 
using a 9-valent PCV (PCV9) in the early 2000s found that the vaccine reduced all-cause 
mortality by 16% (3-28%) (Miller et al., 2011). Following this trial, the WHO recommended 
that global use of PCVs would reduce mortality due to pneumonia in children by 25-30% 
(World Health Organization., 2013). Subsequently, a recent global burden assessment found 
that about half of all fatal lower respiratory tract infections (LRTIs) were caused by 
pneumococcus and a significant proportion of these were, thus, potentially vaccine-
preventable (Troeger et al., 2017). However, a systematic review and meta-analysis of 
randomized controlled studies did not find PCVs to have a statistically significant effect on 
death due to pneumonia (Lucero et al., 2009; Ewald et al., 2016). This may be due to a 
number of reasons, one being that the magnitude of serotype replacement in pneumococcal 
pneumonia is not known and is difficult to measure because of diagnostic, methodological 
and surveillance challenges. In particular, it is difficult to disentangle the contribution of 
vaccine-related changes to natural fluctuations in serotype dynamics in different populations. 
 
1.2.5 PCV Impact on Antibiotic Resistance  
The impact of PCVs on antibiotic resistance among pneumococcal strains causing IPD has 
varied in different part of the world. In 1998, prior to PCV use, the Centre for Disease 
Control and Prevention reported that 24% of strains associated with IPD were non-
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susceptible to penicillin and that serotypes 6B, 9V, 14, 19F, and 23F accounted for 78% of 
penicillin non-susceptible strains (Whitney et al., 2000). Four years after the introduction of 
PCV7 in the US, the rate of IPD caused by penicillin non-susceptible strain decrease from 6.3 
to 2.7 cases per 100,000 and that due to multidrug-nonsusceptible strains also decrease from 
4.1 to 1.7 cases per 100,000 (Kyaw et al., 2006). During the PCV7 era, serotypes 7F and 
19A, among others, emerged mainly through clonal expansion as the most common replacing 
serotypes causing meningitis in Europe and the USA (Waight et al., 2015; Richter et al., 
2013; Hanquet et al., 2010). However, unlike the UK, the emerging serotype 19A strains 
exhibited high rates of resistance to multiple antibiotics in several countries, including France 
and the USA (Janoir et al., 2016; Mahjoub-Messai et al., 2009). In South Africa, two years 
after PCV7 introduction, vaccine effectiveness against all-serotype multidrug-resistant IPD 
was 96% (95% CI, 62%, 100%) among HIV-uninfected children (Cohen et al., 2014). 
Following three years of PCV use, penicillin non-susceptible IPD rates declined by 47% 
(95% CI: 38%, 55%) in South African children <2 years; this was predominantly due to a 
decline in the proportion of penicillin non-susceptible PCV7 serotypes from 70% of isolates 
in 2009 to 47% of isolates in 2012 (Von Gottberg et al., 2014).  
Following the introduction of PCV13, many countries have demonstrated significantly large 
reductions in IPD caused by the additional PCV13 serotypes, including serotype 19A and the 
antimicrobial resistant clones (Moore et al., 2016; Isturiz et al., 2017; Gaviria-Agudelo et al., 
2016; Sader et al., 2019). However, this serotype continues to circulate and cause invasive 
disease, despite widespread use of PCV13 in industrialised countries with established 
immunisation programs (Balsells et al., 2017).  
 
1.3 PHE Surveillance network 
In 1996, a dataset of all IPD reported in England and Wales was created, by linking 
computerised laboratory reports given to Public Heath England (PHE) formerly the Health 
Protection Agency (HPA). This dataset consists of cases in which S. pneumoniae has been 
identified by culture, or more rarely by antigen detection or PCR, in a normally sterile site. 
The isolates are also transferred to PHE Respiratory and Vaccine Preventable Bacteria 
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Reference Unit (RVPBRU) formerly Respiratory and Systemic Infection Laboratory, for 
serotyping (Trotter et al., 2010). In the UK, blood cultures and cerebrospinal fluid samples 
are routinely obtained from patients who require admission to the hospital. Repeat samples 
from sterile sites within 30 days from the same individual were regarded as part of the same 
episode. Antimicrobial susceptibility testing was done according to British Society for 
Antimicrobial Chemotherapy guidelines (Andrews., 2009), and results are available for 
penicillin and erythromycin, together with some clinical information such as whether a 
patient had meningitis. PCR diagnosis became available in PHE on cerebrospinal and pleural 
fluid samples from patients with suspected meningitis or empyema since January 2006, with 
serotyping done with a pneumococcal polysaccharide antigen assay (Sheppard et al., 2011). 
 After the introduction of PCV7 vaccination in September 2006, all patients with IPD in the 
vaccine-eligible cohorts or catch-up group were followed up actively for vaccination history 
and information on clinical presentation, improving case ascertainment of IPD. However, this 
is still nowhere near the active surveillance implemented by the ABCs in the US. It is 
important to emphasise that the enhanced surveillance was only limited to vaccine eligible 
cohort (i.e. under 2 year-olds) and only extended until they turned 5. This age group 
constituted only a very small proportion (<5%) of all the meningitis cases annually and, 
therefore, contributed to a very small number of additional cases of “clinically diagnosed 
meningitis with positive blood cultures”. Excluding these cases had no significant impact on 
the reported trends.  
Before 2010, reporting was voluntary; consequently, there was also an increasing trend in 
ascertainment of cases during the period, as evidenced by a parallel increase in cases of other 
invasive bacterial infections reported to PHE, which continued up until 2009–10 (Flasche et 
al., 2011). 
To correct for this increase, the average percentage annual change in total invasive 
pneumococcal infections from 2000–2006 was calculated for each age group, and this was 
then used to retrospectively increase counts to the projected 2009–2010 level of 
ascertainment, when the increase then stabilise. For example, pre-PCV7 invasive 
pneumococcal disease reports in children younger than 2 years increased by 1·67% annually; 
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thus, for 2005/06, an inflation factor of 1·01674=1·07 was applied to the raw numbers for that 
year (Miller et al., 2011).  
Serotypes 6A and 6C were routinely distinguished from each other from May, 2009, 
onwards, and have therefore been combined in this analysis. Full serotyping within 
serogroups in the PHE reference laboratory started in 2000 (Miller et al., 2011). The 
proportion of total isolates serotyped improved over time, from 50% in 2000/01, to 79% in 
2005/2006, to 90% in 2009/2010, and remained between 91% and 97% in subsequent years 
with variation between age groups. In the same period, the proportion of cases with missing 
age data decreased from 4·4% to 0·1% and the population size increased in most age groups 
(Office for National Statistics., 2011). To correct for these changes, the raw number of yearly 
invasive pneumococcal infections with known age and serotype data were adjusted with the 
assumption that cases with missing age (<1% of cases) and serotype information had the 
same age and serotype distribution as those cases in which this information was known, The 
number of extra cases were then added to the raw numbers in each category. Numbers were 
then further adjusted to 2009–2010 Office for National Statistics population denominators in 
each age group (Office for National Statistics., 2011). Cases prevented were estimated as the 
difference between the expected number of cases by age group, through the use of the 
corrected trends in the absence of vaccination and the observed number of cases after the 
introduction of each vaccine. 
Public Health England has legal permission, provided by Regulation 3 of The Health Service 
(Control of Patient Information) Regulations 2002, to process patient confidential 
information for national surveillance of communicable diseases (http:// 
www.legislation.gov.uk/uksi/2002/1438/regulation/3/ made) and includes Public Health 
England's responsibility to monitor the safety and effectiveness of vaccines. 
The “clinical diagnosis” of meningitis requires a positive pneumococcal culture from a sterile 
site, typically the blood. It is acknowledge that pneumococcal meningitis cases with a 
positive blood but not CSF culture may be missed if they are not reported as “meningitis”. 
This will underestimate the total burden of pneumococcal meningitis, but should not affect 
the trends over time or the vaccine impact analysis in this thesis. 
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In addition, there is the issue of unconfirmed bacterial meningitis where the pathogen may 
not be identified due to diagnostic practices, but there was no evidence of any change in 
diagnostic practices over the surveillance period in this thesis. Indeed, since pneumococcal 
meningitis is such an important diagnosis with significant case fatality as well as long-term 
morbidity, the experience is that any under-reporting is likely to be minimal. In addition, the 
pneumococcus is likely to contribute to a proportion of such cases across all age groups. 
Since such cases will not be picked up in the national pneumococcal surveillance, and 
therefore, the true incidence of pneumococcal meningitis is likely to be higher than that 
reported in the surveillance and thesis. However, even if the overall incidence was lower, the 
trends observed over time – and therefore the impact of PCVs will remain. 
Because of these surveillance factors outlined above, included in this thesis is a pre-PCV 
adjustment to make the pre-vaccine epidemiology comparable to the post-vaccine 
epidemiology. This has involved imputation of missing data and a pre-vaccine trends 
adjustment. Since the data had been corrected for any under-ascertainment in the pre-PCV7 
period, this should help nullify any surveillance artefacts in this analysis. This surveillance is 
sufficiently sensitive to observe large reductions in vaccine-type meningitis cases after the 
introduction of both PCV7 and PCV13.   
The study period in this thesis thus spanned 16 years, 6 years of baseline before PCV7 
vaccination from 2000–01 to 2005–06, 4 years after PCV7 vaccination, from 2006–07 to 
2009–10, and 6 years after PCV13 introduction, from 2010–11 to 20015–16. Study years run 
from July to June.  
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1.4 Aims and Objectives 
The aim of this thesis was to provide novel contribution to knowledge with regards to 
assessing the impact of pneumococcal conjugate vaccines on IPD following the replacement 
of PCV7 with PCV13 in the UK childhood immunisation programme. This thesis focused 
particularly on childhood IPD, with emphasis on severe manifestations of IPD and 
understanding the disease in high-risk populations.  
The specific objectives of the thesis were to: 
1. Undertake a systematic review of the literature to describe the risk, characteristics and 
outcomes of children with PCV failure (i.e. development of vaccine-type IPD in a 
child who was appropriately immunised with PCV for age) [Chapter 3] (Oligbu et al., 
2016)  
2. Elucidate national surveillance data, to estimate the incidence, clinical characteristics 
and outcomes of IPD in children with PCV failure in England and Wales since the 
introduction of the PCV7 programme in 2006 [Chapter 4] (Oligbu et al., 2017a) 
3. Undertake a systematic review of the literature to describe the risk, characteristics and 
outcomes of IPD in children with sickle cell disease during the era of pneumococcal 
conjugate vaccination [Chapter 5] (Oligbu et al. , 2019a)  
4. Use multiple national sources, to describe the risk, clinical characteristics and 
outcomes of IPD in a cohort of children who were identified with sickle cell disease 
through a national neonatal screening programme and who would have been eligible 
for PCV13 [Chapter 6] (Oligbu G et al., 2018)  
5. Evaluate national surveillance data to estimate the impact of PCV7 and PCV13 on the 
pneumococcal meningitis in England and Wales [chapter 7] (Oligbu et al.,  2019b) 
6. Describe a detailed clinical case follow-up of all children suspected to have died of 
IPD in England and Wales since the introduction of PCV7 in 2006 [Chapter 8] 
(Oligbu, et al. 2017b)  
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                                    CHAPTER 8 
 
Discussion 
 
9.1 Pneumococcal Vaccine Failure 
The published articles assessed the impact of pneumococcal conjugate vaccines (PCVs) on 
invasive pneumococcal disease (IPD) especially in children and those with underlying 
comorbidities, particularly children with sickle cell disease (SCD).  In the UK, PCV7 and 
PCV13 were introduced into the national immunisation programme in 2006 and 2010 
respectively, but at variable times in other industrialised countries. These vaccines are highly 
effective in preventing IPD caused by the respective vaccine serotypes (Waight et al., 2015). 
However, the overall reduction was offset by increase in IPD cases due to non-vaccine 
serotypes. Whilst much has been published about PCV7 and its impact on IPD, there was a 
paucity of similar information for PCV13. This thesis provides a new insight into PCV13 and 
it’s impact on IPD.  
Whilst PHE national surveillance monitored disease rates across all age groups in England, 
there were a number of important questions that remained unanswered following PCV13 
implementation. The first part of the study (chapters 3 and 4) aimed to describe the 
characteristics of children with PCV failure, initially through a systematic review of the 
literature, followed by analysis of national surveillance data.  
In chapter 3, a systematic review of all observational studies reporting PCV failures cases 
was performed. This was the systematic review of children with PCV failure. A total of 159 
vaccine failure cases were identified, representing 2.1% of the reported IPD cases from 20 
publications in children aged <5 years. The rate of PCV failure was low, with PCV failure 
cases accounting for only 2% of total IPD cases, irrespective of the vaccine (PCV7, PCV10 
or PCV13) or schedule (2+1, 3+0, 3+1) used in industrialised countries. The review also 
found a high co-morbidity prevalence but a low case fatality rate, which was more likely to 
be associated with underlying comorbidity (Oligbu et al., 2016). Comorbidity prevalence in 
the published literature, relating almost exclusively to PCV7 failures, ranged between 10% 
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and 36%, which was in keeping with the prevalence in UK children with IPD (Ladhani et al., 
2013), with immunosuppression, mainly malignancy, and cardiac conditions predominating. 
These are known risk factors for IPD, irrespective of vaccination status and, therefore, it was 
not surprising that such children were also at increased risk of vaccine failure. 
The use of national surveillance data in England and Wales was the largest cohort study 
assessing vaccine failure cases from the inception of routine PCV in 2006 over an 8-year 
surveillance period in England and Wales. It was also the first published article comparing 
PCV13 with PCV7 vaccine failure cases. In this study, only161 children (<1/100,000 
vaccinated person-years) had PCV failure among 10 birth cohorts (around 700,000 babies per 
birth cohort) over the 8-year surveillance period (Oligbu et al., 2017a). The study confirmed 
that PCV failure was very rare, even when compared with Haemophilus influenzae type b 
(Hib) conjugate vaccine, with a reported vaccine failure rate of 2.2/100000 UK children over 
a 6 year and 5 month period (Heath et al., 2000), and for the meningococcal group C (MenC) 
conjugate vaccine, where 53 vaccine failure cases were identified among <18-year-olds 
during the first 4 years after vaccine introduction (Auckland et al., 2006). Unlike MenC 
vaccine failure cases where the children were previously healthy, but similar to Hib vaccine 
failures, the presence of underlying comorbidities and waning antibodies after vaccination 
were the potential explanations for vaccine failure among children receiving PCV (Heath et 
al., 2000; Auckland et al., 2006). 
Compared to serotypes causing IPD in the pre-PCV7 period, serotypes 6B and 19F were 
over-represented among vaccine failure cases. These two serotypes had the lower antibody 
responses after infant immunisation (Goldblatt et al., 2010) and the lowest serotype-specific 
vaccine effectiveness after PCV7 introduction (49% and 70%, respectively) (Andrews et al., 
2011). Others have also reported a predominance of these two serotypes among PCV7 failure 
cases (Park et al., 2010), which were responsible for more than half of the PCV7 failures in 
our cohort. 
After PCV13 introduction, serotype 3 and 19A were over-represented among vaccine 
failures. Low vaccine effectiveness for these serotypes has been reported in England and 
Wales (Andrews et al., 2014). In infants, serotype 3 elicited the lowest post-primary and post-
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booster antibody responses of the additional PCV13 serotypes (Snape et al., 2010). For this 
serotype, it is estimated that very higher serum immunoglobulin G (IgG) concentrations 
(>2.83 µg/mL) were required for protection against the disease compared to the 
internationally accepted threshold of 0.35 µg/mL (Andrews et al., 2014); such high 
concentrations were rarely attained after vaccination (Snape et al., 2010). 
Unlike other serotypes, the clustering of serotype 19A vaccine failure cases around 12 
months of age may indicate waning immunity after the 2 infant priming doses. It is possible 
that a 3-dose priming schedule before the first birthday might reduce vaccine failure rates by 
inducing higher post–primary immunisation antibody concentrations before the 12-month 
booster, but this would require additional doses and cost. However, the low prevalence of 
PCV7 failures after PCV13 introduction was reassuring and it is likely that PCV13 failures 
will also decline in the coming years as vaccine serotypes stop circulating in highly 
immunised populations such as the UK (Oligbu et al., 2017a). Given that almost a quarter of 
PCV failure cases had underlying risk factor for IPD, the extent of immunological 
investigations for individual children with PCV failure is likely to require careful clinical 
assessment, taking into account the family and past history of serious infections as well as the 
severity of IPD (Oligbu et al., 2017a). An underlying immune deficiency is more likely in 
children who develop IPD after 2 years of age (Gaschignard et al., 2014), and those with 
recurrent IPD (Ingels et al., 2015), but has not been reported for children with PCV failure, 
possibly because this is such a rare event and there was no robust evidence base to 
recommend routine investigations and management of children with PCV failure. Further, 
this work reported that vaccine failure rates were higher after 2 PCV doses in infancy and 
lowest after completion of the recommended 3-dose schedule, most likely because of a 
combination of factors, including higher vaccine effectiveness after 3 doses, lower IPD 
incidence in older ages, and more time for herd protection effects after PCV introduction 
(Oligbu et al., 2017a). Interestingly, it was also observed that children with PCV13 failures 
were more likely to be healthy and develop LRTI, a less severe form of IPD, whereas those 
with PCV7 failures were more likely to have comorbidities and develop septicaemia (Oligbu, 
et al., 2017a).  In agreement with this observation, in a study in Portugal, of the 22 children 
who were appropriately vaccinated with PCV13, 19 children developed complicated 
pneumonia, of which serotype 3 predominated (Silva-Costa et al., 2018).  Similar findings 
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were reported in Barcelona, among the 84 children with IPD, 9 children had PCV13 failure. 
The majority of which were due to pneumonia and serotype 3 was isolated in two-third of the 
cases (Moraga-Llop et al., 2016).  
Taking the findings of the studies presented in chapters 3 and 4, it was reassuring to note very 
low rates of recurrent IPD and deaths among vaccine failure cases, and most cases had an 
identifiable risk factor, such as asplenia, immunosuppression or cochlear implant (Ladhani et 
al., 2013; Alsina et al., 2015; Ingels et al., 2014; Sanz et al., 2014; Mason Jr et al., 2007). On 
the other hand, children with recurrent IPD and no obvious risk factors were more likely to 
have an underlying immune deficiency, irrespective of their previous pneumococcal 
vaccination status (Ingels et al., 2015; Gaschignard et al., 2014). Such children, therefore, 
should be subjected to a thorough immunological assessment and investigation as detailed in 
the publication. 
Chapter 3, in particular, demonstrated the potential strengths of combining outcomes of rare 
events through a systematic review of the literature. However, the lack of detailed 
information on vaccine failure cases in the review was a significant limitation; It is also 
important that future studies report vaccine failure rates using the total number of vaccinated 
children and their at-risk time period so that different vaccines, immunisation schedules and 
populations can be compared. This work also identified a clear need to establish both 
international and national registers for rare outcomes such as vaccine failure, as part of post-
vaccine implementation surveillance in countries with established immunisation programmes 
to allow meaningful analysis of the data collected, and to monitor trends over time. 
 
9.2 IPD and Sickle Cell Disease  
Patients with sickle cell disease (SCD), especially young children, are known to have a very 
high risk of IPD and pneumococcal vaccination is recommended to reduce this risk, along 
with daily penicillin prophylaxis for children less than 5 years of age. The work presented in 
Chapter 5 aimed to systematically review the published literature on the impact of PCVs in 
children with SCD from 2000 to 2017. A total of 9,438 participants aged up to 22 years with 
SCD were included in the final analysis and 182 developed IPD. This identified a very low 
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rate of IPD of 1.9% in children with SCD, many of whom also had other associated 
comorbidities (Oligbu et al., 2019a).The overall CFR in the published studies was 11.5%, 
which, although lower than the 15% reported in industrialised countries prior to PCV 
introduction (Adamkiewicz et al., 2003; Hord et al., 2004; Gaston et al., 1986), remains 
unacceptably high.  
Within the published literature, a few studies had reported a lower IPD rates in children with 
SCD during PCV7 compared with PPV23 (Halasa et al., 2007; Payne et al., 2013). In the US, 
in comparison to the pre-PCV period, the rate of IPD decreased by 93.4% (from 2044 to 134 
cases per 100,000 person-years) (Halasa et al., 2007), and comparing with healthy less than 
18 years old, African-American, there was 53% vs 74% decline (Payne et al., 2013).  
However, the impact of PCV13 had not been well established.  
National surveillance data for England were therefore linked to study the impact of PCV13 
on IPD in children with SCD. Despite an overall decline in IPD incidence, children with SCD 
were still 49 times more likely to develop IPD and 5 times more likely to die of their 
infection compared to their healthy peers (Oligbu et al., 2018a). However, this increased risk 
was substantially lower than the >600 fold increased risk reported in the absence of 
preventive strategies (Overturf et al., 1977). Nearly all IPD episodes in children with SCD 
occurred on or before their 2nd birthday, which is not surprising because this age-group 
struggles to mount protective antibodies against the polysaccharide capsule of encapsulated 
bacteria such as the pneumococcus. 
The study also found that most IPD cases were due to serotypes not covered by PCV13, 
particularly serogroup 15. Others countries with established pneumococcal vaccination also 
reported a disproportionate proportion of IPD cases due to non-PCV serotypes in children 
with SCD compared with children without SCD after PCV introduction (Payne et al., 2013; 
Halasa et al., 2007; Martin et al., 2018; Navalkele et al., 2017). Although, there were no cases 
of meningitis in our SCD cohort, the CFR of 27% in children with homozygous SCD (HbSS) 
was much higher than that reported for overall childhood IPD (4.4%), IPD in children with 
comorbidities (9.1%) and even pneumococcal meningitis (11.0%) in England and Wales 
(Ladhani et al., 2013). However, two of the three IPD-related deaths in this study occurred in 
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prematurely-born infants, who are also at increased risk of IPD and fatal outcomes 
(Shinefield et al., 2002). 
The lack of penicillin resistance among pneumococcal isolates causing IPD in our cohort of 
children with SCD may suggest that these children were not adherent to penicillin 
prophylaxis at the time of infection. Nationally, surveillance of children with SCD found that 
97% of children with SCD were prescribed penicillin prophylaxis by 6 months, with only 
seven refusals during the follow-up period of this study (Streetly et al., 2018). A recent 
systematic review found that compliance rates for long-term medications in children with 
SCD ranged from 16% to 89% (Duncan et al., 2016). Given that most cases of IPD in SCD 
are no longer vaccine preventable, Healthcare professionals need to work more closely with 
families with SCD to emphasise the importance of penicillin prophylaxis, facilitate rapid 
access to healthcare facilities, allay misguided beliefs and explore any barriers (Oligbu et al., 
2018a). This study also highlighted the need for higher valency PCV or, preferably, a 
universal vaccine targeting all pneumococci irrespective of their capsular serotype (Ladhani 
et al., 2015).  
A consistent finding within the two publications presented in chapter 5 and chapter 6 was that 
after PCV7 introduction and subsequent replacement with PCV13, serogroup 15 appeared to 
be particularly common cause of IPD among children with SCD, accounting for half of IPD 
cases. Genomic analysis of invasive isolates and murine SCD studies have suggested that 
some pneumococcal strains may be particularly adapted to cause invasive disease in children 
with SCD (Carter et al., 2014). In a recent review of S. pneumonia isolated in England and 
Wales from multiple sources, serotype 15A has increased in all areas compared to pre-
conjugate vaccine era and also showing triple resistance to penicillin, macrolides and 
tetracyclines. In addition, most of these multidrug-resistant 15A isolates were sequence type 
(ST) 63 variants, whereas susceptible 15A isolates were clonally diverse (Sheppard et al., 
2016).  However, the virulence and aggressiveness of this serogroup compared to other more 
prevalent serotypes is not known and additional studies beyond the scope of this thesis are 
needed to better understand this observed association. 
In many industralised countries, PPV23 is recommended for at-risk children from 2 years of 
age, including SCD. This vaccine aims to protect against 11 additional serotypes, including 
15B, which is now the commonest cause of IPD in patients with SCD. Unlike PCVs, 
however, PPV23 is a polysaccharide vaccine and therefore, only activates a B-cell immune 
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response leading to a predominantly IgM response without an immunological memory 
response, as well as rapid waning of protection compared to polysaccharide conjugate 
vaccines (Kelly et al., 2005). The effectiveness of PPV23 in children, especially those at risk 
of IPD, remains controversial (Borrow et al., 2012). It is therefore advisable, that until a 
conjugate vaccine containing serogroup 15 becomes available, any protection afforded by 
PPV23, even if short-term, is likely to be beneficial in this highly vulnerable group who 
appear to be susceptible to some of the additional PPV23 serotypes, particularly serogroup 
15. 
One of the potential limitations with the review (Chapter 5) was the lack of information on 
compliance or adherence with penicillin prophylaxis. However, the importance of penicillin 
prophylaxis cannot be emphasised enough, especially in children aged <5 years, because of 
its potential to protect against all pneumococcal infections and not just the vaccine serotypes 
(Yawn et al., 2014). Children with SCD need to continue taking penicillin prophylaxis until a 
universal vaccine targeting all pneumococci irrespective of their capsular serotype becomes 
available (Ladhani et al., 2015). 
 
9.3 MENINGITIS 
Meningitis is the most severe clinical presentation of IPD and is associated with a 
significantly higher case fatality rate, with high rates of sequelae among survivors. Several 
countries with established pneumococcal vaccination programmes reported a differential 
impact of PCV on pneumococcal meningitis (Ben-Shimol et al., 2017; Alari et al., 2016; Hsu 
et al., 2009; Ruiz-Contreras et al., 2017; Tsai et al., 2008; Liset et al., 2015).  
In chapter 7, the impact of the introduction of PCV on pneumococcal meningitis in England 
and Wales was assessed. This was the largest epidemiological study that described ‘the effect 
of PCV on pneumococcal meningitis’ over a 16-year surveillance period between 2000/01 
and 2015/16. There were 84,473 laboratory-confirmed IPD cases across all age groups in 
England and Wales, including 4,160 cases (4.9%) with meningitis.  Although, large 
declines in IPD incidence were observed after both PCV7 and PCV13 introductions, a 
differential impact on pneumococcal meningitis compared to non-meningitis presentations 
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was observed.  The annual incidence of pneumococcal meningitis remained unchanged after 
PCV7 introduction, but declined by 48% after PCV13 replaced PCV7, including a 70% 
decline in children < 5 years of age (Oligbu et al., 2019b).  
In France, too, PCV7 implementation led to a rebound in the incidence of pneumococcal 
meningitis, with a 2.2-fold increase in childhood meningitis cases (with a 6.5 fold increase in 
cases among < 2 years-old) (Alexandre et al., 2010), accompanied by a 44% reduction after 
PCV13 replaced PCV7 (Alari et al., 2016; Cohen et al., 2016). In contrast, many other 
European and other countries with established PCV programmes reported a decline in 
pneumococcal meningitis after both PCV7 and PCV13 implementation (Imöhl et al., 2015; 
Ricketson et al., 2014; Moreira et al., 2016; De Oliveira et al., 2016; Polkowska et al., 2017; 
Ruiz-Contreras et al., 2017; Shinjoh et al., 2017; Jacobs et al., 2017). 
There were also significant shifts in the serotypes causing pneumococcal meningitis over 
time. Prior to PCV7 implementation, serotype 14 was the most frequent serotype causing 
meningitis in England and Wales (Trotter et al., 2010). This was consistent with other 
countries including Belgium, Germany, and Brazil (Verhaegen et al., 2003; Vieira et al., 
2007; Imöhl et al., 2010). During the PCV7 era, serotypes 7F and 19A, among others, 
emerged mainly through clonal expansion, as the most common replacing serotypes causing 
pneumococcal meningitis in US and Europe (Waight et al., 2015; Richter et al., 2013; 
Hanquet et al., 2010). However, unlike the UK, the emerging serotype 19A strains in other 
countries, including the US and France, exhibited high rates of resistance to multiple 
antibiotics (Janoir et al., 2016; Mahjoub-Messai et al., 2009). Additionally, meningitis due to 
serotype 7F has been associated with more severe disease in children, with increased rates of 
complications and a higher case fatality rate compared with other serotypes (Rückinger et al., 
2009). 
The replacement of PCV7 with PCV13, which offer protection against both serotypes 7F and 
19A, led to a rapid reduction in IPD, including meningitis, due to these serotypes across all 
age groups, and consequently reduction in the strains non-susceptible to antibiotics in 
countries with high rates of antibiotic-resistant pneumococcal strains (Ben-Shimol et al., 
2018). Currently, meningitis due to PCV13 serotypes is rare and the non-PCV13 serotypes 8 
and 12F are the main replacing serotypes causing meningitis across all age groups in England 
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and Wales. A common feature shared among countries with established PCV13 programme 
is the high proportion of cases (70-80%) that are now due to non-PCV13 (Olarte et al., 2015; 
Levy et al., 2016; Kleynhans et al., 2019). The predominance of serotype 8, in particular 
appears unique to our population (Oligbu et al., 2019b). The finding of lower odds of 
meningitis but a higher risk of death with serotype 8 meningitis is novel (Oligbu et al., 
2019b), and needs to be verified in other populations. 
Pneumococcal meningitis is associated with a higher CFR compared to other clinical 
presentations and the CFR did not change over the years, even after implementation of two 
PCVs and despite significant reductions in disease incidence (Hirose et al. 2015; Ruiz-
Contreras et al., 2017; Jacobs et al., 2017). This is likely to be because, although the risk of 
pneumococcal meningitis may be lower after PCV introduction, once meningitis develops, 
the outcomes in terms of long-term complications or death are similar, irrespective of the 
infecting serotype (Liset et al., 2015). This supports previous experimental work that suggests 
that death and sequalae following pneumococcal meningitis is a result of a 
hyperinflammatory host response to the bacteria (Meli et al., 2006). 
The overall impact of PCVs on pneumococcal meningitis has been less prominent compared 
to other clinical presentations in England and Wales. Our findings and those of others 
highlight the importance of monitoring vaccine-preventable disease by their major clinical 
presentations. Although these vaccines are highly effective in preventing IPD caused by 
vaccine serotypes, the overall reduction, however, has been offset by increase in replacement 
disease due to non-vaccine serotypes (Ladhani et al., 2018). Because these serotypes have 
only emerged after the pneumococcal vaccines were introduced, there is very little 
knowledge of the risk, clinical severity and outcomes of pneumococcal meningitis caused by 
these new and emerging serotypes.  
 
9.4 DEATHS 
In industrialised countries, the case fatality rate for IPD is low, but little is known about the 
children who die of IPD. The final analysis presented in chapter 8 was the largest prospective 
national surveillance using multiple data sources to obtain detailed information from 
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clinicians on all childhood deaths attributable to IPD in England and Wales between 4 
September 2006 and 3 September 2014, a period covering 8 surveillance years and 10 birth 
cohorts of children eligible for PCV. There were 150 IPD-related deaths from 3,146 IPD 
cases. The CFR of 4.8% showed that IPD in young children was rarely associated with a fatal 
outcome, with more than half (59%) of deaths in infants, mainly < 3months old (28%). These 
infants were too young to benefit from the infant immunisation programme. PCV 
introduction was associated with a 69% reduction in IPD-related mortality rate in children 
aged <5 years since the first year of the immunisation program (Oligbu et al., 2017b), but, 
unfortunately, this work was unable to compare with the pre-PCV7 rates, when IPD-related 
mortality rates were likely to be even higher, because the surveillance only began after PCV 
implementation in the UK 
The serotypes responsible for IPD-related deaths reflected those that were circulating at the 
time. After PCV7 introduction in England and Wales, an increase in the additional PCV13 
and other serotypes was observed (Miller et al., 2011), which was associated with an increase 
in LRTI presentations and a decrease in the other clinical presentations (Ladhani et al., 2013), 
yet nearly half the IPD-related deaths remained due to meningitis, irrespective of the 
pneumococcal serotype (Oligbu et al., 2017b). Population-based studies have identified 
significant associations between specific pneumococcal serotypes and death among patients 
presenting with septicaemia (Harboe et al., 2009) and pneumonia (Weinberger et al., 2010) 
but not with meningitis (Alanee et al., 2007). 
PCVs were developed to protect against the most virulent serotypes and it was hoped that any 
replacing serotypes would have lower invasive potential. This assertion was partly true in that 
non-vaccine serotypes have only partly replaced the large niche in IPD cases left by the PCV 
serotypes (Waight et al., 2015; Ladhani et al., 2018). In Spain, significant declines in IPD-
related mortality rates have been reported in adults following both PCV7 and PCV13 
introduction (Grau et al., 2016). In children, such impact has been more difficult to 
demonstrate because of the smaller number of childhood cases and deaths.  
A major risk factor for death in children with IPD was the presence of underlying 
comorbidities.  Previous reports following PCV7 introduction have supported these findings, 
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in addition to meningitis as independent risk factors for death in children with IPD (Wang et 
al., 2019; Ladhani et al., 2013; Ladhani et al., 2012). IPD-related CFR was 9.1% in children 
with comorbidities compared with 3.5% in those without (Ladhani et al., 2013). The work 
presented in this thesis has shown that, a third of fatal cases had an underlying comorbidity 
compared to an overall prevalence of 15% among children with IPD after PCV7 introduction, 
with malignancy/immunosuppression and congenital heart disease predominating (Ladhani et 
al., 2013). Further, the fact that more than one-third of children (mainly infants) died outside 
the hospital or in the emergency department suggests either a very rapid onset or parental 
failure to recognise the warning symptoms and signs of serious infection. Raising awareness 
may improve earlier recognition of the sick child, leading to earlier treatment with better 
outcomes. 
9.5 Summary and Clinical Implication   
The introduction of PCVs has had a major impact on pneumococcal disease in young 
children, additional impact was observed in adult because of herd effects but to a variable 
extent. This thesis has demonstrated that these vaccines were highly effective in reducing 
vaccine type IPD and most cases are now due to non-PCV13 serotypes, which are now 
associated with higher comorbidity prevalence. A change in clinical presentation following 
vaccine introduction was also observed. Reassuringly, vaccine failures and fatality following 
IPD remain low, with serotypes 3 and 19A isolated in majority of the failure cases; this is not 
surprising as these two serotypes had the lowest immunogenicity as well as the lowest 
vaccine effectiveness estimates among PCV13 serotypes (Andrews et al., 2014). In addition, 
recent carriage studies suggests these 2 serotypes have the highest carriage among the 
vaccine serotypes since the introduction of conjugate vaccines (Southern., et al. 2018). It is 
therefore possible that the current PCV13 will continues to provide some immunity against 
disease caused by these persisting PCV13 serotypes in vaccinated children but not capable of 
providing indirect (herd) protection to the population or prevent carriage. Other industrialised 
countries with established PCV13 programmes have also been unsuccessful in controlling 
these serotypes (Hanquet et al., 2019; Balsells et al., 2017). 
However, children with sickle cell disease continue to be at higher risk of IPD and fatalities 
despite all the available interventions compared with other children with comorbidities, and   
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serogroup 15 was responsible for majority of IPD in this cohort. The differential increase in 
fatality in this cohort could be adduced to the hypothesis that serotypes with a low invasive 
potential often associated with a higher fatality in those with underlying condition 
(Brueggemann etal., 2003; Zemlickova., et al. 2010). In the study by Makwana and 
colleague, using the same cohort, children with sickle cell disease, were more likely to die of 
IPD compared with other forms of immunosuppression, including malignancy, especially 
among 24- to 59-month olds. Interestingly, this age group, when compared with children 
without comorbidity, the CFR was remarkably similar (Makwana et al., 2018). This 
reassuring finding is likely to be a result of rapid access to medical care for 
immunosuppressed children presenting with fever and strict protocol adherence with low 
threshold for initiating antimicrobial therapy by clinicians (NICE., 2012). It is therefore 
possible that with improved rapid access to healthcare facilities by children with SCD when 
they become sick and maintaining high adherence to penicillin prophylaxis, there could be a 
reduction in CFR in children with SCD.  
 
Among the different forms of IPD, meningitis remains an independent risk factor for death, 
with non-PCV serotypes, especially serotypes 8, 12F, and 22F now responsible for the 
majority of cases. The effect of these serotypes on mortality remained questionable, but this 
work found serotype 8 more likely to cause fatality in this cohort despite a low carriage rate 
(Southern et al., 2018). This finding is yet to be corroborated in other studies. Other recent 
studies have been unable to identify any differences in the clinical characteristics of children 
with pneumococcal meningitis even though cases due to PCV13 serotypes declined rapidly 
after PCV13 introduction and those due to non-PCV13 serotypes increased (Olarte et al., 
2015) 
However, compared to other conjugate vaccines, such as Haemophilus influenzae type b 
(Hib) and group C Meningococcal (MenC), the control of IPD through vaccination has been 
more challenging and the overall benefits of the current PCVs is likely to decline in the 
developed countries because of serotype replacement disease, but will continue to have a 
major impact in developing countries where most pneumococcal deaths still occur.  
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9.6 Conclusions 
The childhood pneumococcal vaccination programme has led to a significant reduction in the 
incidence of invasive pneumococcal disease, including meningitis, across all age groups 
through a combination of the direct and indirect protection offered by the national 
immunisation programme with high vaccine uptake. However, compared to other clinical 
presentation, there was a lower than expected impact on pneumococcal meningitis, with case 
fatality rates due to meningitis remaining relatively unchanged across the age groups.  
This thesis has also demonstrated that these PCVs are highly effective in preventing IPD due 
to the respective vaccine serotypes. The rate of PCV failure, irrespective of the vaccine used 
or schedule, was very low, as was CFR in children with PCV failure. Most children with 
PCV13 failure were healthy, developed LRTI, and survived their infection without long-term 
complications. The continuing low prevalence of PCV7 failures after PCV13 introduction is 
reassuring and it is likely that PCV13 failure will also decline in the coming years.  
However, children with SCD remained at a very high risk of pneumococcal disease and death 
despite these measures of daily penicillin prophylaxis as well as pneumococcal vaccination. 
The majority of serotypes causing IPD in children with SCD are no longer vaccine 
preventable, therefore every effort should be made to ensure that these children adhere to 
penicillin prophylaxis and pneumococcal vaccines. Further studies should assess whether 
improving parental education to seek early medical help might also achieve better outcomes. 
Finally, given that most IPD cases, including meningitis are now due to non-PCV13 
serotypes, including most fatal IPD cases, additional strategies will be required to reduce 
childhood pneumococcal deaths in countries with established pneumococcal vaccination 
programmes. Further studies are therefore needed to assess the risk factors, clinical course 
and outcomes of pneumococcal meningitis due to these replacing serotypes. Meanwhile, 
alternative strategies such as protein-based serotype-independent will be needed to curb the 
problem of serotype replacement disease. 
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                                      CHAPTER 9 
 
 Future steps  
 
This chapter will detail research I intend to conduct over the next 4 years of my career and 
build on work described earlier in this thesis. I will outline a series of research questions that 
have arisen through this thesis and detail studies that attempt to address these.  
 
10.1 Characteristics of Children with Pneumococcal Meningitis in the United Kingdom 
and Republic of Ireland 
 
10.1.1 Research question 
What is the clinical burden (rate of hospitalisation including PICU admission) of 
pneumococcal meningitis in the United Kingdom and Republic of Ireland?  
Is this era of non-vaccine serotypes, what are the characteristics of children with 
pneumococcal meningitis? 
This grant (Sir Peter Tizard bursary - received) is offered to junior paediatric consultants to 
conduct a national British Pediatric surveillance (BPSU) study after a national competition. 
This proposed study builds on the findings from the epidemiological study of pneumococcal 
meningitis in the UK (Chapter 7) and childhood deaths following the introduction of 
conjugate vaccines (Chapter 8).  
 
10.1.2 Background 
The introduction of pneumococcal vaccines have been associated with a rapid decline in 
pneumococcal disease, including meningitis caused by the vaccine serotypes (Waight et al. 
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2015; Oligbu et al., 2019). However, the overall reduction, has been offset by a small 
increase in disease due to non-vaccine serotypes (Miller et al., 2011; Oligbu et al., 2019b). 
Currently, nearly all pneumococcal infections in children are caused by non-vaccine 
pneumococcal serotypes. Since these serotypes have only emerged after the pneumococcal 
vaccines were introduced, there is very little knowledge of the risk, clinical severity and 
outcomes of pneumococcal meningitis caused by these new and emerging serotypes. 
This study will aim to understand the clinical severity, presenting features, acute 
management, clinical course and outcomes of this replacing serotypes causing meningitis. 
The results will be compared with the national standard of care for children with serious 
infections. 
 
10.1.3 Research plan 
Study design 
Prospective observational cohort study. 
Primary outcome measures 
 To estimate the incidence of childhood pneumococcal meningitis in children aged <16 
years in the UK and Republic of Ireland in the era of pneumococcal conjugate 
vaccines. 
 Describe the characteristics of children with pneumococcal meningitis. 
 
Inclusion Criteria:  
Any child aged <16 years with CSF positive for pneumococcus by culture and/or PCR. 
 
Exclusion Criteria 
Children who do not fulfil the inclusion criteria. 
 
10.1.4 Methodology 
Paediatricians will be asked to notify any case of pneumococcal meningitis in the previous 
month through the BPSU orange card system. Paediatricians notifying a case will be asked to 
complete a detailed questionnaire about the case. The questionnaire will also request 
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information about the infecting pneumococcal serotype, which should be known to the 
paediatrician. If this is not the case, then the study team will ask the paediatrician to contact 
the local microbiology team or, if needed, the respective national reference laboratory in each 
of the nations for the information.  
Pneumococcal meningitis cases identified through national surveillance in place within 
individual nations will be used as an alternate data source to estimate the total burden of 
disease in the UK and Ireland.  
For the 12-month follow-up, we will send a standard questionnaire to the paediatricians 
reporting a case of pneumococcal meningitis through the BPSU to assess possible long-term 
complication following pneumococcal meningitis. 
 
10.1.5 Potential benefit  
Understanding the disease caused by these new, emerging non-vaccine serotypes, will enable 
pediatricians to provide parents of children with pneumococcal meningitis a more accurate 
picture of the course of illness and long-term prognosis. 
It will also allow for a better estimation of the burden of childhood pneumococcal meningitis 
in the individual nations and across the UK and Ireland by linking multiple data sources. In 
terms of service benefit, the results will be compared with the national standard of care for 
children with serious infections with the aim of identifying areas of improvement to achieve 
better outcomes. The study results are likely to inform future pneumococcal vaccine policy. 
 
 
10.2 Neurodevelopmental Outcomes of pneumococcal meningitis in children  
10.2.1. Research question 
Are the newly emerging serotypes more likely to cause severe disease and neurological 
complications compared to the vaccine serotypes? 
This is a follow-on study from the one outlined above using the same cohort. A grant 
application has been made to Meningitis Research Foundation. This proposed study also 
builds on the findings of the effect of PCV on pneumococcal meningitis in Chapter 7.  
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10.2.2 Background  
Survivors of pneumococcal meningitis (PM) are more likely than any other causes of 
meningitis to suffer from neurological and other serious long-term complications (Dery and 
Hasbun., 2007; Neuman and Wald., 2001; Epstein et al., 1992). In a meta-analysis including 
48 studies, 32% had long-term complications, including hearing loss, seizures, brain injury 
and blindness (Jit., 2010).  A number of studies have reported long-term effect of other 
common bacterial causes of meningitis and health-related quality of life (HRQoL) outcomes, 
including physical, emotional, psychological, social, and overall well-being of sufferers of 
bacterial meningitis (Olbrich et al., 2018; Giorgakoudi et al., 2018) (Oostenbrink et al., 
2002), but  studies on pneumococcal meningitis are lacking in the UK, particularly in this era 
of this new and emerging serotypes. Thus, this area of research has been identified as an area 
in need of further and more recent evidence. Such evidence on the long-term consequences of 
pneumococcal meningitis in terms of quality-adjusted life-years (QALYs) for both survivors 
and carers will be valuable in modelling the impact of preventive interventions in children at 
risk. 
10.2.3 Research plan 
Study design 
Prospective observational cohort study. 
Primary outcome measures 
 Identify the long-term neurological sequelae (neurodevelopment outcomes) of 
meningitis survivors. 
 Assess health related quality of life of survivors and caregivers.  
 Compare outcome with available data prior to the introduction of conjugate vaccines 
and with other common bacterial causes of meningitis.  
 
10.2.4 Methods 
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My study proposes to follow-up a cohort of 100 children affected by pneumococcal 
meningitis (aged < 2 years) recruited through the above BPSU national pneumococcal 
meningitis surveillance study (Project 257619) due to start in January 2020 in collaboration 
with over 20 years of PHE established pneumococcal surveillance. Additional individual 
parental consent will be obtained from affected families. Affected children will be followed 
up after 12 months of the illness.  
It is proposed that two aspects of long-term sequelae be assessed: neurodevelopmental 
impairment and quality of life.  
The Bayley Scales of Infant Development (BSID-III) is a standard series of measurements 
used primarily to assess the motor (fine and gross), language (receptive and expressive), and 
cognitive development of infants and toddlers, ages 0-3. Raw scores of successfully 
completed items are converted to scale scores and to composite scores. At the completion of 
the test the assessor will provide a report on the test, including in addition to the scores, 
comments on the test conditions and any other factors that may have influenced the outcomes 
of the test.  
At the time of these visits, parents will also be asked to complete the Infant and Toddler 
Quality of Life Questionnaire (ITQOL) of children between 2 months and 5 years old. This 
well-validated questionnaire provides a comprehensive assessment of health status and 
health-related quality of life, including physical, psychological and social domains (Landgraf 
et al., 2013). The ITQOL consists of 103 items (10 multi-item scales and 2 single-item scales) 
that generally refer to the situation during the past 4 weeks. Per scale, the items that have 4, 5 
or 6 response options are summed up with equal weight per item and transformed into a 0 
(worst possible score) to100 (best possible score) scale.  
 
Data obtained from the above BPSU study will be linked with this study and this will enable 
assessment of the relevance and significance of the information obtained from the BPSU 
study to their long-term outcomes.  
 
10.2.5 Potential benefit of the study   
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Understanding the neurodevelopment outcomes and clinical burden caused by these new, 
emerging non-vaccine serotypes, will enable paediatricians to provide parents of children 
with pneumococcal meningitis a more accurate picture of the long-term prognosis. The study 
results are likely to inform future pneumococcal vaccine policy and shape healthcare delivery 
to affected families. 
 
10.3 Recurrent IPD in Children  
10.3.1 Research Question 
What are the characteristics of children with recurrent invasive pneumococcal diseases? 
This proposed study builds on work outlined in chapters 3 and 4.  
 
10.3.2 Background 
Certain clinical conditions have been associated with increased risk of IPD, for example, 
children with sickle cell disease (SCD), those with human Immunodeficiency Virus (HIV) 
infections, asplenia, nephrotic syndrome, immunodeficiency other than HIV, children on 
immunosuppressive therapy and conditions associated with cerebrospinal fluid leak (van 
Hoek et al., 2012). In addition, primary immunodeficiency diseases, especially children with 
complement deficiencies and B-cell dysfunction have been reported to have a high risk of 
IPD (Ram et al., 2010).  
Although type-specific immunity results from prior infection, recurrent infections by the 
same pneumococcal type can occur, especially in immune-compromised hosts. It is estimated 
that 2.3% to 4.4% of IPD cases are due to recurrent infection, and more than half (52% to 
92%) of these occur in children with underlying comorbidity (Einarsdottir et al., 2005; Mason 
Jr et al., 2007; King et al., 2003). 
In this study, the work will aim to describe the clinical characteristics and serotype 
distribution of children with recurrent IPD in our pediatric population, as well as identify the 
underlying risk factors.  
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10.3.3 Research plan 
Study design 
Prospective enhanced national surveillance study. 
Primary outcome measures 
 Describe the clinical characteristics of children with recurrent IPD. 
 Identify underlying risk factors for recurrent IPD. 
Case Definition 
A recurrent IPD was defined as 2 or more episodes of IPD in the same individual at least one 
month apart. Among recurrent IPDs, relapse will be differentiated if the same pneumococcal 
isolate is identified (defined as 2 strains with the same clonal type and/or serotype) and 
reinfection IPD if it is different (defined as 2 strains with different serotype and/or clonal 
type). 
10.3.4 Methods 
Eligible children will be identified using PHE LabBase2 database (PHE’s national database).  
National Health Service (NHS) laboratories in England and Wales electronically report all 
significant infections to PHE and routinely submit all invasive pneumococcal isolates to the 
PHE national reference laboratory for confirmation and serotyping (Waight et al., 2015). As 
part of enhanced national surveillance, general practitioners and hospital pediatricians for <5 
year-olds with laboratory-confirmed IPD completed a short questionnaire on vaccination 
history, known comorbidities at the time of IPD, complications, and outcomes. Completed 
questionnaires from general practitioners will be returned to PHE Colindale. Data on children 
with recurrent infection will be retrieved for analysis. 
 
10.3.5 Potential benefit 
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This surveillance will better estimate the burden of recurrent invasive childhood 
pneumococcal infection in England and Wales, and also identify areas of improvement in 
terms of management of these cases and to achieve better outcome.  
Understanding the risk factors will enable pediatricians to provide parents of children with 
some preventative measures. 
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Appendix 1: Search Strategy on PCV Failure in Children: A systematic review of the 
literature 
Database: Embase 
Search for: limit 17 to (English language and yr="2000 -Current") 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     ((vaccin* or immuni?ation) adj3 fail*).mp. [mp=title, abstract, heading word, drug trade name, 
original title, 
device manufacturer, drug manufacturer, device trade name, keyword]  
2     (invasive pneumococcal disease or streptococcal pneumonia or IPD or vaccine type disease).mp. 
[mp=title, abstract, 
heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade 
name, keyword] 
3     ((vaccin* or immuni?ation) adj3 (timeline or timetable or schedule)).mp. [mp=title, abstract, 
heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]  
4     (PCV7 or PCV10 or PCV13 or PCV9).mp. [mp=title, abstract, heading word, drug trade name, 
original title, devicemanufacturer, drug manufacturer, device trade name, keyword]  
5     (7-valent or 10-valent or 13-valent or 9-valent).mp. [mp=title, abstract, heading word, drug trade 
name, originaltitle, device manufacturer, drug manufacturer, device trade name, keyword]  
6     (child* or youth* or toddler* or teen* or young adult or adolescen* or baby or babies or infan* or 
paediatric* orpediatric*).mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drugmanufacturer, device trade name, keyword]  
7     exp immunization 
8     child  
9     infant  
10     adolescent  
11     exp Pneumococcus vaccine 
12     exp pneumococcal infection 
13     1 or 2 or 12  
14     3 or 7  
15     4 or 5 or 11 
16     6 or 8 or 9 or 10  
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17     13 and 14 and 15 and 16  
18     limit 17 to (english language and yr="2000 -Current")  
 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 
<1946 to Present> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Vaccination 
2     ((vaccin* or immuni?ation) adj3 fail*).mp. [mp=title, abstract, original title, name of substance 
word, subjectheading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, uniqueidentifier]  
3     (invasive pneumococcal disease or streptococcal pneumonia or IPD or vaccine type disease).mp. 
[mp=title, abstract,original title, name of substance word, subject heading word, keyword heading 
word, protocol supplementary concept word,rare disease supplementary concept word, unique 
identifier]  
4     ((vaccin* or immuni?ation) adj3 (timeline or timetable or schedule)).mp. [mp=title, abstract, 
original title, nameof substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare diseasesupplementary concept word, unique identifier]  
5     exp Immunization Schedule 
6     (PCV7 or PCV10 or PCV13 or PCV9).mp. [mp=title, abstract, original title, name of substance 
word, subject headingword, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, uniqueidentifier]  
7     (7-valent or 10-valent or 13-valent or 9-valent).mp. [mp=title, abstract, original title, name of 
substance word,subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary conceptword, unique identifier]  
8     (child* or youth* or toddler* or teen* or young adult or adolescen* or baby or babies or infan* or 
paediatric* orpediatric*).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word,protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier]  
9     exp child/ or exp infant 
10     exp Adolescent 
11     exp Pneumococcal Vaccines 
12     exp Pneumococcal Infections 
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13     8 or 9 or 10  
14     6 or 7 or 11  
15     2 or 3 or 12  
16     4 or 5  
17     13 and 14 and 15 and 16 
18     limit 17 to yr="2000 -Current"  
19     limit 18 to English language  
 
